These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23640345)

  • 41. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.
    Scheffel RS; Dora JM; Siqueira DR; Burttet LM; Cerski MR; Maia AL
    Eur J Endocrinol; 2013 Jun; 168(6):K51-4. PubMed ID: 23487538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
    J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
    Massicotte MH; Borget I; Broutin S; Baracos VE; Leboulleux S; Baudin E; Paci A; Deroussent A; Schlumberger M; Antoun S
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2401-8. PubMed ID: 23543666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vandetanib (Caprelsa) for medullary thyroid cancer.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
    [No Abstract]   [Full Text] [Related]  

  • 47. Vandetanib for the treatment of thyroid cancer: an update.
    Karras S; Anagnostis P; Krassas GE
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):469-81. PubMed ID: 24502390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer.
    Xian TC; Yang MY; Zhang XL; Wang J; Luo Y
    Horm Metab Res; 2024 Sep; 56(9):649-653. PubMed ID: 38278145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
    Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
    [No Abstract]   [Full Text] [Related]  

  • 51. Vandetanib for the treatment of non-small-cell lung cancer.
    Wong HL; de Boer RH
    Expert Opin Pharmacother; 2011 Oct; 12(14):2271-8. PubMed ID: 21819274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel therapies for thyroid cancer.
    Krajewska J; Jarzab B
    Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
    Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
    Kreissl MC; Bastholt L; Elisei R; Haddad R; Hauch O; Jarząb B; Robinson B; Colzani R; Foster M; Weiss R; Schlumberger M
    J Clin Oncol; 2020 Aug; 38(24):2773-2781. PubMed ID: 32584630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
    Valerio L; Bottici V; Matrone A; Piaggi P; Viola D; Cappagli V; Agate L; Molinaro E; Ciampi R; Tacito A; Ramone T; Romei C; Elisei R
    Endocr Relat Cancer; 2020 Jan; 27(2):97-110. PubMed ID: 31804969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of vandetanib in the management of medullary thyroid cancer.
    Brassard M; Rondeau G
    Biologics; 2012; 6():59-66. PubMed ID: 22500115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.